Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
Stocks in this Quantisnow insightHealth Care
Historical context for TARA
Across the 18 sessions after earlier TARA headlines, the stock closed higher 10 times and lower 8 times, with a median move of 4.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | TARA | SPY |
|---|---|---|---|
| May 13, 2026 | Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update | +1.0% | +0.6% |
| Apr 28, 2026 | Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting | +1.4% | -0.5% |
| Mar 10, 2026 | Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update | -0.7% | -0.2% |
| Mar 4, 2026 | Analyst initiated coverage on Protara Therapeutics with a new price target | +0.8% | +0.7% |
| Feb 24, 2026 | TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | -26.4% | +0.7% |
| Feb 19, 2026 | Protara Therapeutics to Participate in Upcoming Investor Conferences | +7.2% | -0.3% |
Quantisnow market dataNASDAQ
TARA
Protara Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2014
Get push alerts for TARA
Full TARA profile on Quantisnow Follow TARA and get a push notification the moment its next story breaks.